Thrivent Financial for Lutherans Boosts Holdings in Sanofi (NASDAQ:SNY)

Thrivent Financial for Lutherans raised its stake in shares of Sanofi (NASDAQ:SNY) by 36.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,943,761 shares of the company’s stock after purchasing an additional 514,542 shares during the period. Thrivent Financial for Lutherans’ holdings in Sanofi were worth $93,774,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Signaturefd LLC lifted its holdings in Sanofi by 2.3% during the fourth quarter. Signaturefd LLC now owns 38,200 shares of the company’s stock valued at $1,842,000 after purchasing an additional 853 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of Sanofi by 0.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 112,181 shares of the company’s stock valued at $5,411,000 after buying an additional 578 shares during the last quarter. Natixis Advisors LLC raised its position in shares of Sanofi by 1.2% in the fourth quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock valued at $140,350,000 after buying an additional 35,828 shares during the last quarter. Brandes Investment Partners LP raised its position in shares of Sanofi by 3.6% in the fourth quarter. Brandes Investment Partners LP now owns 2,194,938 shares of the company’s stock valued at $105,862,000 after buying an additional 76,092 shares during the last quarter. Finally, Aviso Financial Inc. raised its position in shares of Sanofi by 1.1% in the fourth quarter. Aviso Financial Inc. now owns 41,837 shares of the company’s stock valued at $2,018,000 after buying an additional 457 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SNY shares. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Sanofi stock opened at $59.11 on Wednesday. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The stock has a market cap of $150.01 billion, a P/E ratio of 23.74, a PEG ratio of 1.01 and a beta of 0.58. The company has a 50-day moving average price of $54.03 and a 200 day moving average price of $52.85. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.